pathogen
evolut
major
public
health
concern
enorm
societ
consequ
around
world
pathogen
evolv
quickli
allow
jump
multipl
host
speci
human
eg
sar
coronaviru
ebola
viru
woolhous
et
al
becom
virul
evad
immun
pressur
within
human
eg
influenza
viru
grenfel
et
al
becom
resist
drug
use
combat
particular
drug
resist
result
numer
death
increas
hospit
prolong
treatment
addit
cost
born
human
health
center
diseas
control
prevent
estim
econom
cost
drug
resist
order
ten
billion
dollar
year
unit
state
alon
cdc
pharmaceut
intervent
play
critic
role
effort
control
epidem
pathogen
urgent
need
understand
evolut
spread
drug
resist
pathogen
share
common
biolog
featur
allow
adapt
rapidli
extrem
select
pressur
impos
exampl
drug
observ
timescal
pathogen
popul
larg
size
high
mutat
rate
short
gener
time
like
gener
drug
resist
mutat
short
amount
time
pathogen
also
encompass
wide
varieti
organ
includ
eukaryot
prokaryot
virus
mean
effort
understand
pathogen
evolv
drug
resist
need
account
factor
variabl
genom
size
rang
kilobas
kb
rna
virus
mani
megabas
mb
plasmodium
falciparum
variabl
mutat
rate
per
base
pair
per
gener
eukaryot
rna
virus
altern
method
genet
exchang
includ
viral
horizont
gene
transfer
bacteria
clonal
vs
recombin
form
reproduct
see
box
divers
mode
genet
exchang
recombin
addit
scale
drug
resist
evolv
vari
wide
exampl
hiv
drug
resist
mostli
evolv
within
patient
rare
transmit
wheeler
et
al
wherea
pathogen
eg
malaria
drug
resist
often
transmit
host
make
certain
drug
ineffect
larg
fraction
new
patient
hyde
prevent
least
manag
drug
resist
pathogen
imper
understand
evolutionari
aspect
problem
howev
evolutionari
biologist
tradit
left
studi
drug
resist
medicin
epidemiolog
commun
read
huijben
chang
recent
year
interest
popul
genet
work
done
natur
popul
pathogen
featur
review
chang
least
part
driven
avail
genet
data
varieti
pathogen
new
field
emerg
use
larg
amount
genet
data
new
theoret
advanc
world
popul
genet
work
directli
aim
find
way
prevent
drug
resist
evolut
spread
wherea
work
basic
natur
mostli
use
pathogen
model
system
learn
evolut
gener
best
case
learn
lesson
prevent
resist
gener
evolutionari
principl
simultan
aim
review
introduc
research
differ
field
new
excit
work
drug
resist
evolut
happen
intersect
popul
genet
medic
field
virolog
infecti
diseas
perhap
importantli
review
intend
advertis
strength
use
natur
pathogen
popul
studi
evolutionari
principl
well
strength
use
evolutionari
theori
better
understand
dynam
infecti
diseas
end
present
five
case
studi
intersect
evolutionari
theori
pathogen
drug
resist
five
exampl
chosen
meant
exhaust
way
exampl
showcas
evolutionari
question
context
differ
pathogen
uniqu
biolog
differ
genom
size
method
genet
exchang
reproduct
recombin
see
box
describ
follow
five
exampl
select
sweep
map
malaria
parasit
p
falciparum
resist
antimalari
drug
artemisinin
great
exampl
popul
genet
method
origin
develop
sexual
recombin
eukaryot
organ
human
could
appli
p
falciparum
experi
high
rate
sexual
recombin
map
drug
resist
mutat
p
falciparum
allow
research
track
preval
artemisinin
resist
worldwid
role
epistasi
oseltamivir
tamiflu
resist
influenza
evolut
spread
oseltamivir
resist
influenza
unexpect
even
though
causal
mutat
oseltamivir
resist
known
thought
costli
viral
fit
spread
wide
phylogenet
method
allow
research
discov
mutat
interact
resist
mutat
amelior
detriment
effect
allow
resist
mutat
spread
influenza
becom
model
help
research
understand
import
genet
interact
site
cours
evolut
potenti
predict
futur
evolut
import
stand
genet
variat
sgv
also
refer
minor
variant
treatment
failur
human
immunodefici
viru
hiv
drug
resist
mutat
well
known
hiv
evolut
drug
resist
happen
independ
differ
patient
make
possibl
determin
import
sgv
drug
resist
hiv
sever
studi
found
sgv
de
novo
mutat
contribut
drug
resist
hiv
clonal
interfer
dynam
mycobacterium
tuberculosi
drug
resist
mutat
also
well
known
tuberculosi
track
mutat
recent
studi
reveal
clonal
interfer
play
larg
role
evolutionari
dynam
within
patient
examin
dynam
offer
insight
strain
emerg
also
provid
rare
look
natur
popul
evolv
without
recombin
popul
structur
analysi
core
accessori
genom
staphylococcu
aureu
mrsa
staphylococcu
aureu
reproduc
clonal
yet
drug
resist
often
acquir
via
spread
mobil
genet
element
horizont
gene
transfer
gene
cassett
sccmec
confer
methicillin
resist
genealog
core
genom
mrsa
reveal
rel
lineag
spread
across
globe
phylogenet
analysi
sccmec
reveal
methicillin
resist
aris
local
scale
five
exampl
use
illustr
grow
avail
sequenc
data
facilit
applic
popul
genet
method
import
question
evolut
drug
resist
three
recent
studi
cheeseman
et
al
et
al
miotto
et
al
examin
pattern
ld
haplotyp
homozygos
p
falciparum
genom
identifi
region
chromosom
associ
artemisinin
resist
locu
later
character
locu
ariey
et
al
three
studi
benefit
greatli
deep
sampl
p
falciparum
multipl
popul
display
artemisinin
drug
resist
phenotyp
slow
parasit
clearanc
rate
other
noedl
et
al
dondorp
et
al
data
allow
author
contrast
genom
pattern
strain
geograph
locat
display
slow
parasit
clearanc
rate
phenotyp
vs
first
major
studi
cheeseman
et
al
examin
genom
data
sampl
three
popul
lao
thailand
cambodia
resist
observ
thailand
cambodia
cheeseman
et
al
data
set
offer
opportun
contrast
thai
cambodia
sampl
lao
discov
put
loci
confer
resist
artemisinin
cheeseman
et
al
util
approach
identifi
genom
region
underli
resist
artemisinin
first
author
use
sabeti
et
al
fst
lewontin
krakauer
statist
identifi
region
signific
candid
select
least
one
popul
statist
particularli
appropri
multipopul
data
set
design
contrast
genom
signatur
two
popul
box
cheeseman
et
al
found
region
discov
associ
posit
select
studi
examin
differ
drug
valid
approach
second
cheeseman
et
al
examin
associ
region
slow
parasit
clearanc
rate
phenotyp
identifi
two
adjac
polymorph
snp
kb
apart
sampl
chromosom
show
signific
associ
cheeseman
et
al
perform
fine
map
region
appli
ehh
statist
box
visual
confirm
extend
haplotyp
homozygos
pattern
region
chromosom
characterist
select
sweep
similar
cheeseman
et
al
studi
et
al
examin
multipl
popul
cambodia
thailand
bangladesh
signatur
select
associ
slow
parasit
clearanc
phenotyp
cambodian
thai
sampl
show
resist
phenotyp
author
use
effici
associ
emma
see
box
kang
et
al
test
associ
snp
data
set
parasit
clearanc
phenotyp
therebi
identifi
four
snp
significantli
associ
includ
two
chromosom
conjunct
associ
test
et
al
appli
sabeti
et
al
fst
lewontin
krakauer
cambodia
popul
use
thai
bangladeshi
popul
comparison
popul
author
found
polymorph
chromosom
previous
identifi
emma
test
also
signific
fst
valu
et
al
use
haploview
barrett
et
al
visual
extend
haplotyp
homozygos
region
miotto
et
al
examin
locat
west
africa
asia
found
except
high
amount
popul
substructur
within
cambodia
upon
closer
examin
author
found
three
four
cluster
p
falciparum
found
western
cambodia
show
slow
parasit
clearanc
rate
slow
decay
ld
loss
haplotyp
divers
fourth
cluster
preval
northeastern
cambodia
show
characterist
lead
author
conclud
western
cambodia
harbour
least
three
distinct
popul
p
falciparum
particular
one
subpopul
resist
strain
p
falciparum
show
singl
haplotyp
extend
across
half
chromosom
corrobor
evid
cheeseman
et
al
et
al
locu
implic
resist
artemisinin
cheeseman
et
al
et
al
miotto
et
al
abl
local
put
locu
chromosom
strongli
associ
slow
parasit
clearanc
phenotyp
recent
ariey
et
al
abl
identifi
caus
mutat
high
confid
ariey
et
al
use
vitro
drug
select
techniqu
subject
parasit
line
high
dose
artemisinin
year
compar
sequenc
data
select
line
clonal
popul
experienc
select
author
identifi
eight
mutat
seven
gene
present
artemisinin
treatment
group
absent
control
group
ariey
et
al
narrow
list
candid
conclud
mutat
appear
kelch
gene
chromosom
appear
time
artemisinin
resist
develop
treatment
group
determin
whether
concord
presenc
mutat
kelch
gene
parasit
cambodia
ariey
et
al
sequenc
locu
mutat
present
parasit
sampl
patient
show
phenotyp
patient
differ
geograph
locat
cambodia
found
mutat
kelch
gene
strongli
associ
slow
clearanc
phenotyp
observ
locat
malaria
preval
extend
analysi
ariey
et
al
identifi
mutat
kelch
gene
significantli
associ
artemisinin
resist
sever
studi
confirm
find
ariey
et
al
ashley
et
al
examin
geograph
extent
resist
track
preval
mutat
kelch
gene
see
fig
author
found
sever
singl
point
mutat
kelch
significantli
associ
slow
parasit
clearanc
rate
recent
work
cheeseman
et
al
miotto
et
al
et
al
tun
et
al
also
precis
map
origin
extent
mutat
associ
artemisinin
resist
see
fig
ghorbal
et
al
use
system
introduc
mutat
implic
artemisinin
resist
ariey
et
al
kelch
produc
slow
parasit
clearanc
phenotyp
demonstr
first
direct
link
mutant
kelch
characterist
phenotyp
work
expand
upon
straimer
et
al
confirm
role
multipl
mutat
addit
genet
factor
confer
artemisinin
resist
five
exampl
review
studi
exampl
use
classic
statist
method
find
associ
kelch
gene
artimisinin
resist
p
falciparum
perhap
familiar
popul
geneticist
eukaryot
pathogen
high
rate
recombin
sequenc
analysi
p
falciparum
genom
amen
tradit
genom
scan
approach
clever
stratif
sampl
gave
addit
power
genom
scan
combin
novel
experiment
method
research
abl
find
locu
recent
strong
select
respons
evolut
resist
artimisinin
identif
kelch
gene
popul
genet
method
offer
clear
exampl
standard
methodolog
identifi
select
sweep
power
identifi
causal
locu
given
p
falciparum
manipul
experiment
confirm
comput
predict
organ
attract
choic
futur
studi
drug
resist
especi
sinc
malaria
continu
costli
diseas
new
loci
may
unknown
interact
among
site
genom
give
rise
phenomenon
call
epistasi
effect
one
mutat
site
depend
presenc
absenc
mutat
site
epistat
interact
exist
ensur
fit
effect
drug
resist
mutat
depend
genet
background
emerg
epistasi
drug
resist
evolut
character
sever
vitro
studi
includ
case
five
interact
mutat
involv
cefotaxim
resist
escherichia
coli
produc
predict
mutat
order
weinreich
et
al
hundr
interact
mutat
determin
viral
fit
antiretrovir
resist
hiv
hinkley
et
al
case
oseltamivir
resist
mutat
shown
detriment
effect
viral
fit
first
identifi
laboratori
ive
et
al
abe
et
al
herloch
et
al
led
research
believ
virus
carri
unlik
clinic
consequ
ive
et
al
resist
strain
subsequ
reach
global
frequenc
nearli
flu
season
bloom
other
show
mutat
reduc
amount
fold
neuramindas
reach
host
cell
surfac
therebi
reduc
viru
fit
hypothes
secondari
mutat
site
influenza
genom
may
act
amelior
deleteri
effect
mutat
permit
reach
high
global
frequenc
bloom
et
al
bloom
colleagu
took
sequenc
creat
phylogenet
tree
found
five
nonsynonym
mutat
separ
strain
common
strain
found
strongli
neg
fit
effect
ad
mutat
one
one
strain
found
two
five
mutat
strong
effect
amount
neuraminidas
cell
surfac
virus
two
mutat
longer
reduc
fit
viru
absenc
oseltamivir
creat
viru
mutat
fit
compar
wild
type
presenc
oseltamivir
viru
much
higher
fit
wild
type
bloom
et
al
phylogeni
statu
three
mutat
shown
fig
subsequ
studi
also
identifi
potenti
epistat
interact
mutat
hemagglutinin
neuraminidas
impact
viral
fit
may
influenc
spread
oseltamivir
resist
hensley
et
al
gint
et
al
behera
et
al
taken
togeth
result
suggest
epistasi
profound
impact
evolut
resist
oseltamivir
allow
resist
mutat
spread
global
popul
work
also
provid
cautionari
evid
clinic
assess
drug
resist
mutat
secondari
mutat
interact
epistat
drug
resist
mutat
import
factor
need
incorpor
make
predict
epidemiolog
consequ
drug
resist
mutat
know
even
deleteri
drug
resist
mutat
spread
emerg
permiss
background
tell
us
pay
close
attent
identifi
monitor
potenti
epistat
interact
virolog
surveil
extent
epistasi
gener
featur
adapt
evolut
theoret
empir
work
predict
adapt
may
enrich
epistat
interact
draghi
et
al
draghi
plotkin
gong
et
al
rajon
masel
szendro
et
al
gong
bloom
mean
epistasi
like
play
gener
role
adapt
evolut
limit
specif
case
studi
also
mean
research
interest
adapt
need
model
system
test
theori
regard
epistasi
influenza
resist
evolut
form
model
test
popul
genet
predict
regard
role
epistasi
adapt
evolut
oseltamivir
resist
evolut
provid
first
evalu
methodolog
potenti
predict
site
within
protein
interact
one
anoth
base
sequenc
data
phylogenet
tree
bloom
colleagu
initi
predict
mutat
potenti
candid
posit
epistat
interact
use
phylogenet
method
bloom
glassman
infer
stabil
effect
mutat
show
inde
restor
surfac
express
wild
type
level
absenc
oseltamivir
bloom
et
al
meanwhil
kryazhimskiy
et
al
examin
hemagglutinin
neuraminidas
sequenc
multipl
influenza
strain
success
predict
known
epistat
interact
collin
et
al
anoth
mutat
see
fig
addit
mutat
identifi
bloom
et
al
methodolog
base
statist
rank
specif
amino
acid
substitut
within
phylogeni
predict
evolut
influenza
intrigu
prospect
evolutionari
geneticist
briefli
discuss
discuss
studi
shown
phylogenet
method
affirm
theoret
predict
regard
pattern
epistasi
also
predict
epistat
interact
may
clinic
import
also
establish
connect
protein
phylogeni
fit
may
prove
use
futur
work
popul
genet
infecti
diseas
person
start
treatment
blood
sampl
taken
sequenc
viru
see
schutten
overview
genotyp
assay
sanger
sequenc
hiv
start
treatment
standard
clinic
practic
sequenc
simen
et
al
et
al
sequenc
proteas
revers
transcriptas
integras
gene
use
determin
whether
drug
resist
mutat
present
high
frequenc
result
help
clinician
patient
choos
combin
drug
start
treatment
hirsch
et
al
major
viral
popul
patient
carri
resist
mutat
inform
use
choos
drug
regimen
work
specif
viru
howev
drug
resist
mutat
low
popul
frequenc
less
detect
standard
sequenc
protocol
simen
et
al
import
question
therefor
whether
sgv
present
patient
whether
allow
viral
popul
adapt
evolv
drug
resist
import
studi
pared
et
al
use
aspcr
determin
whether
drug
resist
mutat
alreadi
present
minor
variant
viral
popul
patient
patient
origin
took
part
clinic
trial
blood
sampl
start
treatment
treatment
failur
applic
store
treatment
failur
defin
viru
detect
blood
level
higher
expect
given
patient
treatment
author
focus
two
import
resist
mutat
revers
transcriptas
gene
patient
treat
combin
revers
transcriptas
inhibitor
patient
found
either
alreadi
present
minor
variant
mostli
around
frequenc
could
detect
mutat
patient
patient
minor
variant
treatment
fail
success
patient
without
minor
variant
treatment
fail
success
altogeth
treatment
fail
patient
consid
patient
without
detect
sgv
treatment
fail
patient
mean
patient
failur
attribut
presenc
minor
variant
see
fig
estim
pared
et
al
treatment
failur
come
sgv
may
underestim
author
look
presenc
two
drug
resist
mutat
may
detect
variant
case
howev
two
mutat
import
treatment
look
result
fairli
similar
differ
estim
describ
less
direct
method
studi
role
sgv
evolut
hiv
drug
resist
develop
one
us
pen
data
previou
studi
margot
et
al
look
excess
adapt
earli
treatment
found
studi
interest
resist
evolut
happen
constant
rate
second
third
year
treatment
year
viru
acquir
resist
patient
previous
viru
without
drug
resist
constant
rate
evolut
drug
resist
also
observ
sever
trial
eg
uk
collabor
group
hiv
drug
resist
uk
chic
studi
group
other
year
treatment
sgv
present
treatment
probabl
play
role
like
reflect
evolut
resist
de
novo
mutat
first
year
treatment
expect
new
mutat
sgv
contribut
evolut
resist
resist
evolv
patient
viral
popul
suggest
sgv
play
role
margot
et
al
patient
total
first
year
treatment
expect
number
peopl
resist
year
rate
seen
year
year
realiti
peopl
resist
expect
see
fig
estim
sgv
lead
resist
patient
one
may
note
total
number
fail
patient
much
higher
pared
et
al
may
stricter
criterion
treatment
success
copi
pared
et
al
vs
copi
margot
et
al
also
patient
similar
treatment
pared
studi
margot
studi
light
differ
overal
rate
evolut
two
studi
perhap
surpris
see
estim
rate
evolut
sgv
similar
pen
use
third
data
set
estim
rate
evolut
resist
due
trial
long
treatment
interrupt
patient
danel
et
al
estim
suggest
estim
fairli
robust
pen
adapt
sgv
discuss
extens
literatur
howev
rel
studi
attempt
quantifi
rel
import
mode
adapt
altogeth
result
studi
hiv
suggest
sgv
play
import
quantit
predict
role
treatment
failur
particular
diseas
sgv
may
also
play
larg
role
treatment
outcom
diseas
caus
pathogen
other
cancer
bozic
et
al
sequenc
use
determin
whether
sgv
exist
patient
prior
treatment
thu
inform
clinic
decis
individu
patient
apart
clinic
relev
particular
exampl
hiv
drug
resist
evolut
also
valid
evolutionari
theori
regard
adapt
sgv
orr
betancourt
hermisson
pen
barrett
schluter
recombin
thought
evolutionarili
adapt
allow
differ
adapt
mutat
resid
differ
genet
background
popul
appear
togeth
fisher
muller
felsenstein
addit
unlink
posit
select
trait
deleteri
passeng
mutat
mitig
effect
link
select
hill
robertson
birki
walsh
good
desai
popul
recombin
mutat
remain
genet
background
origin
occur
therefor
multipl
posit
select
trait
enter
popul
simultan
differ
background
trait
recombin
augment
instead
must
compet
rise
frequenc
popul
muller
process
known
clonal
interfer
gerrish
lenski
clonal
interfer
extens
model
rouzin
et
al
desai
fisher
park
krug
marten
hallatschek
neher
investig
laboratori
experi
miral
et
al
pepin
wichman
kvitek
sherlock
lang
et
al
system
exist
allow
us
test
predict
natur
popul
global
influenza
seem
evolv
clonal
across
year
strelkowa
intrahost
popul
nonrecombin
bacteria
allow
mani
evolutionari
trajectori
compar
much
shorter
time
scale
although
evid
hiv
experi
clonal
interfer
within
patient
recombin
complic
studi
pandit
de
boer
also
strong
interest
clonal
evolut
cancer
sampl
differ
time
point
often
much
harder
cancer
tuberculosi
hiv
make
cancer
studi
system
difficult
ding
et
al
walter
et
al
intrahost
evolut
tuberculosi
provid
fairli
straightforward
way
examin
clonal
interfer
vivo
understand
extent
slow
evolutionari
process
recombin
allel
frequenc
pool
resequenc
case
reconstruct
haplotyp
see
larg
genom
size
mb
drug
resist
mutat
long
time
cours
infect
mean
pattern
divers
track
time
although
previou
studi
shown
presenc
compet
clonal
lineag
tuberculosi
popul
patient
use
neutral
marker
et
al
navarro
et
al
use
understand
drug
resist
mutat
better
understand
evolutionari
dynam
popul
among
patient
infect
strain
tuberculosi
drug
resist
evolv
within
patient
treatment
track
frequenc
drug
resist
mutat
time
singl
patient
observ
clonal
interfer
lineag
carri
benefici
mutat
real
time
sun
et
al
conduct
first
analysi
kind
track
drug
resist
allel
frequenc
three
patient
across
least
two
time
point
first
patient
entir
free
drug
resist
mutat
onset
treatment
second
time
point
sampl
four
segreg
drug
resist
mutat
final
time
point
sampl
singl
drug
resist
mutat
divid
among
strain
includ
contain
drug
resist
mutat
present
second
time
point
suggest
tuberculosi
rapidli
acquir
resist
mutat
differ
strain
compet
due
lack
recombin
second
patient
enter
studi
tuberculosi
popul
fix
certain
drug
resist
mutat
rpob
remain
sensit
antibiot
rifampicin
eighteen
month
later
patient
popul
whose
genet
composit
domin
differ
drug
resist
mutat
rpob
resist
rifampicin
suggest
success
sweep
altern
drug
resist
mutat
lead
strain
eldholm
et
al
perform
similar
studi
much
greater
sequenc
depth
singl
patient
follow
month
extens
drug
resist
acquir
pathogen
patient
start
standard
antibiot
regimen
pyrazinamid
rifampicin
isoniazid
given
increasingli
uncommon
drug
tuberculosi
popul
acquir
drug
resist
mutat
dynam
clonal
interfer
shown
fig
base
data
eldholm
et
al
allel
frequenc
measur
sever
time
point
allel
similar
frequenc
trajectori
assum
background
clone
therefor
clonal
frequenc
chang
infer
across
time
eldholm
et
al
identifi
drug
resist
mutat
reach
frequenc
seven
ultim
fix
shown
green
suggest
clonal
interfer
may
purg
strongli
select
drug
resist
mutat
even
reach
high
frequenc
shown
blue
knowledg
posit
select
drug
resist
mutat
also
allow
us
understand
dynam
hitchhik
mutat
alreadi
background
drug
resist
mutat
aros
eldholm
et
al
found
mutat
directli
associ
drug
resist
also
fix
popul
week
sampl
mutat
may
neutral
compensatori
posit
select
adapt
unrel
drug
also
possibl
slightli
deleteri
rose
frequenc
due
linkag
benefici
mutat
eldholm
et
al
may
note
case
drug
resist
mutat
ad
haplotyp
one
one
suggest
individu
mutat
lead
increas
fit
troubl
part
rational
behind
use
multipl
drug
time
make
much
harder
pathogen
evolv
resist
need
acquir
multipl
mutat
time
suggest
imperfect
drug
penetr
may
explain
evolut
resist
tuberculosi
despit
multidrug
therapi
lipsitch
levin
et
al
studi
clonal
interfer
thu
far
larg
investig
within
experiment
theoret
model
uniqu
applic
studi
clonal
dynam
natur
popul
human
pathogen
tuberculosi
use
presenc
drug
resist
mutat
posit
control
strong
direct
select
abl
better
understand
evolutionari
dynam
clonal
evolv
pathogen
popul
tuberculosi
although
current
detail
data
patient
includ
deep
coverag
entir
genom
across
multipl
time
point
appear
case
clonal
interfer
tuberculosi
popul
occur
way
similar
seen
laboratori
experi
knowledg
hundr
drug
resist
mutat
avail
afford
sequenc
expect
see
mani
studi
dynam
tuberculosi
near
futur
especi
look
forward
studi
popul
genet
use
understand
genet
pattern
associ
divers
treatment
outcom
staphylococcu
aureu
human
commens
known
caus
danger
skin
blood
stream
infect
well
abil
becom
resist
major
antibiot
lowi
stryjewski
corey
addit
methicillin
resist
first
emerg
also
grow
number
case
resist
antibiot
includ
vancomycin
quinolon
aminoglycosid
streptogramin
oxazolidinon
rifamycin
lowi
stryjewski
corey
mrsa
particularli
deadli
exampl
mortal
rate
patient
mrsa
bloodstream
infect
report
de
kraker
et
al
usa
infect
death
per
year
caus
mrsa
stockman
drug
resist
aris
via
new
mutat
within
genom
singl
clone
strahilevitz
hooper
howden
et
al
via
horizont
gene
transfer
clone
coomb
et
al
even
via
horizont
gene
transfer
anoth
bacteri
speci
hanssen
ericson
sollid
bloemenda
et
al
malachowa
deleo
smyth
et
al
staphylococcu
aureu
strain
acquir
methicillin
resist
via
mobil
genet
element
sccmec
like
via
transduct
defin
box
maslanova
et
al
integr
cassett
gene
bacterium
chromosom
genom
aureu
mbp
total
mbp
compos
core
genom
mbp
compos
accessori
genom
common
method
analys
genom
aureu
isol
multilocu
sequenc
type
mlst
standard
set
housekeep
gene
core
genom
sequenc
categor
allel
type
allow
placement
isol
defin
clonal
complex
enright
day
enright
et
al
feil
et
al
maiden
et
al
mlst
histor
appli
core
genom
reveal
aureu
highli
clonal
speci
rel
recombin
event
core
genom
robinson
enright
mlst
appli
intern
collect
isol
appear
small
number
clonal
lineag
respons
infect
exampl
oliveira
et
al
appli
mlst
mrsa
isol
hospit
across
europ
south
america
usa
found
five
clone
caus
infect
oliveira
et
al
find
emerg
thought
methicillin
resist
like
spread
across
popul
aureu
rel
clone
acquir
sccmec
clonal
expand
ie
genomewid
sweep
kreiswirth
et
al
et
al
feil
enright
howev
closer
analysi
popul
structur
aureu
accessori
genom
reveal
differ
stori
first
decad
mrsa
outbreak
found
strain
caus
vs
infect
display
distinct
clinic
genet
differ
differ
may
erod
address
later
tend
resist
wider
array
antibiot
often
caus
blood
stream
infect
individu
addit
medic
condit
tend
virul
caus
virul
gene
also
transmit
via
hgt
often
caus
skin
infect
otherwis
healthi
individu
david
daum
chua
et
al
clinic
differ
partli
mediat
mobil
genet
element
call
sccmec
chromosom
gene
cassett
confer
resist
methicillin
also
confer
resist
antibiot
katayama
et
al
hanssen
ericson
sollid
interestingli
genet
chang
within
gene
cassett
track
success
epidem
wave
mrsa
katayama
et
al
chamber
deleo
extens
work
done
investig
sourc
spread
mobil
element
phylogenet
inform
sequenc
adapt
factor
right
sccmec
current
classifi
type
subtyp
use
mutat
orient
segment
within
cassett
et
al
number
studi
show
popul
structur
aureu
differ
strain
david
daum
mediavilla
et
al
stryjewski
corey
strain
thought
aris
clone
newli
acquir
sccmec
cassett
sourc
popul
like
staphylococcu
speci
epidermidi
wu
et
al
hanssen
et
al
meric
et
al
found
strain
tend
carri
longer
sccmec
type
ii
iii
element
clonal
background
wherea
strain
tend
carri
shorter
sccmec
type
iv
v
element
divers
clonal
background
enright
et
al
robinson
enright
david
daum
coomb
et
al
exampl
earli
pandem
could
rel
neatli
classifi
five
clonal
complex
musser
kapur
fitzgerald
et
al
enright
et
al
robinson
enright
contrast
research
began
analys
strain
respons
emerg
health
threat
found
strain
display
divers
stronger
associ
clonal
type
geograph
locat
chua
et
al
david
daum
coomb
et
al
sccmec
type
iv
element
alon
found
enter
least
nine
differ
clonal
complex
aureu
lina
et
al
clinic
genet
differ
mrsa
erod
modern
pandem
mainli
due
emerg
strain
seed
increas
number
hospit
outbreak
chamber
deleo
david
daum
mediavilla
et
al
hsu
et
al
studi
mrsa
infect
citi
san
francisco
california
found
mrsa
infect
acquir
commun
liu
et
al
unit
state
current
predomin
clone
call
typic
contain
sccmec
type
iv
respons
vast
major
infect
addit
caus
hospit
outbreak
seybold
et
al
chamber
deleo
mathemat
model
predict
strain
eventu
replac
strain
tradit
categor
render
categori
far
less
use
dagata
et
al
success
strain
potenti
mediat
arriv
sccmec
type
iv
cassett
may
particularli
suit
recurr
horizont
transfer
confer
faster
growth
rate
littl
fit
cost
okuma
et
al
diep
et
al
chamber
deleo
mediavilla
et
al
clinic
genet
differ
strain
erod
modern
pandem
emphasi
differ
within
recent
literatur
instead
attent
move
toward
leverag
new
sequenc
technolog
maiden
et
al
achiev
higher
resolut
global
pattern
methicillin
resist
acquisit
overal
analys
core
genom
mrsa
strain
suggest
rel
clone
dispers
wide
across
globe
robinson
enright
analys
accessori
genom
mrsa
suggest
new
strain
emerg
local
via
frequent
de
novo
transfer
sccmec
element
word
appear
clonal
expans
rel
core
genom
accessori
genom
frequent
goe
sweep
illustr
lina
et
al
appli
mlst
core
genom
sccmec
element
found
associ
clonal
complex
background
sccmec
element
sequenc
type
author
therefor
conclud
sccmec
appear
transfer
repeatedli
across
distinct
clonal
complex
particularli
case
sccmec
iv
repeatedli
within
clonal
complex
suggest
sccmec
spread
sweep
chua
et
al
show
anoth
studi
mrsa
geograph
genet
distant
isol
ie
distantli
relat
core
genom
nevertheless
rel
conserv
accessori
element
includ
sccmec
type
iv
chua
et
al
suggest
transfer
happen
often
sweep
anoth
exampl
studi
et
al
author
use
improv
sequenc
type
method
core
accessori
genom
investig
genet
relationship
within
singl
clonal
lineag
belong
clonal
complex
use
isol
across
countri
six
contin
contrast
lower
resolut
studi
came
analys
core
genom
sequenc
found
phylogenet
clade
within
clonal
lineag
addit
analys
sccmec
sequenc
reveal
least
independ
transfer
sccmec
occur
clonal
group
alon
acquisit
appear
occur
local
rather
singl
acquisit
dissemin
global
fig
could
refer
case
multipl
origin
adapt
sccmec
element
soft
sweep
pen
hermisson
author
estim
previou
calcul
rate
sccmec
acquisit
least
order
magnitud
low
taken
togeth
know
genet
divers
core
genom
nevertheless
contain
close
relat
resist
allel
frequent
transfer
occur
even
within
clonal
lineag
make
understand
evolutionari
histori
allel
complic
allel
transmit
independ
clonal
expans
core
genom
lineag
nevertheless
studi
drug
resist
aureu
illustr
research
achiev
fine
resolut
demograph
adapt
histori
aureu
use
improv
sequenc
technolog
case
facilit
explor
core
accessori
genom
research
begin
use
sequenc
aureu
even
finer
resolut
evolutionari
histori
mrsa
outbreak
possibl
exampl
holden
et
al
abl
pinpoint
popul
size
chang
geograph
origin
specif
clone
harri
et
al
abl
construct
transmiss
pathway
hospit
outbreak
staff
patient
thu
grow
avail
sequenc
data
sequenc
technolog
provid
abil
determin
resist
may
gener
unconstrain
global
transmiss
dynam
instead
track
local
spatial
scale
present
research
opportun
use
sequenc
tool
monitor
transmiss
network
within
hospit
limit
number
infect
overal
transmiss
repeat
evolut
drug
resist
bacteri
popul
capabl
hgt
present
import
interest
problem
reconstruct
popul
structur
spatial
distribut
resist
field
popul
genet
tradit
lean
heavili
use
fruit
fli
yeast
escherichia
coli
human
model
organ
howev
becom
clear
mani
pathogen
also
excel
model
system
pathogen
evolut
model
evolutionari
system
mani
advantag
pathogen
receiv
lot
attent
biomed
research
consequ
well
studi
extens
sampl
pathogen
alreadi
function
model
organ
lab
eg
influenza
foll
et
al
hiv
van
opijnen
berkhout
polio
acevedo
et
al
e
coli
toprak
et
al
allow
research
assess
characterist
popul
genet
epidemiolog
relev
laboratori
popul
exampl
cell
surfac
express
assay
perform
previous
mention
studi
oseltamivir
resist
influenza
pathogen
system
research
also
appli
known
select
pressur
precis
laboratori
environ
thu
allow
measur
organ
respons
select
addit
pathogen
evolv
drug
resist
quickli
repeatedli
within
patient
case
mani
replic
evolutionari
histori
studi
hiv
hcv
tb
etc
pathogen
also
among
organ
genet
sequenc
data
avail
popul
genet
analysi
aureu
sequenc
influenza
sequenc
hiv
sequenc
malaria
sequenc
releas
genbank
alon
benson
et
al
access
may
moreov
decreas
cost
sequenc
make
amount
new
data
pathogen
increas
exponenti
throughout
review
highlight
use
sequenc
data
popul
genet
theori
studi
pathogen
evolutionari
model
system
believ
pathogen
evolut
continu
fruit
area
research
evolutionari
biologist
fundament
insight
lead
benefici
public
health
consequ
sequenc
data
emerg
forese
futur
specif
question
would
like
see
address
intersect
popul
genet
drug
resist
pathogen
first
expect
work
bridg
vs
dynam
eg
lythgo
fraser
import
consider
genet
variat
creat
select
within
host
howev
process
infect
yet
receiv
suffici
attent
expect
work
includ
time
seri
deep
sampl
pathogen
tradit
studi
level
tuberculosi
work
describ
review
good
exampl
new
work
influenza
also
done
roger
et
al
second
deeper
sampl
time
seri
becom
increasingli
possibl
estim
select
pressur
pathogen
estim
epistat
interact
mutat
work
method
current
use
identifi
mutat
evalu
select
virus
grown
cell
cultur
lou
et
al
foll
et
al
hope
find
use
clinic
sampl
taken
infect
patient
extend
method
patient
data
potenti
give
research
abil
studi
evolutionari
dynam
pathogen
within
patient
entir
cours
infect
anoth
import
goal
evolutionari
studi
pathogen
increas
predict
power
pathogen
evolut
recent
predict
evolut
seem
like
scienc
fiction
recent
work
chang
percept
possibl
addit
predict
phylogenet
methodolog
mention
discuss
epistasi
influenza
method
use
shape
protein
phylogeni
predict
evolutionari
trajectori
evalu
use
influenza
data
neher
et
al
work
show
predict
low
evolut
occur
big
step
much
higher
evolut
proce
small
step
neher
et
al
although
tend
fix
attent
larg
adapt
event
drug
resist
immun
escap
evolut
small
step
may
common
previous
expect
bhatt
et
al
strelkowa
gong
et
al
organ
like
influenza
new
vaccin
manufactur
everi
year
applic
new
predict
methodolog
use
popul
genet
theori
luksza
potenti
groundbreak
hope
work
drug
resist
review
offer
glimps
grow
field
intersect
studi
pathogen
evolut
evolutionari
genet
also
hope
illustr
field
studi
benefit
greatli
review
contribut
excit
futur
field
author
design
studi
contribut
write
edit
manuscript
baw
wrote
chapter
influenza
nrg
wrote
chapter
malaria
zja
wrote
chapter
mrsa
aff
wrote
chapter
tb
psp
wrote
chapter
hiv
